nificant long-term morbidity in survivors (1) . Although multiple clinical strategies are known to improve oxygenation in ALI/ARDS, the only strategy that clearly has been shown to reduce mortality for patients with ALI is use of low-tidalvolume ventilation (2) . Because adjunctive strategies such as prone positioning, inhaled vasodilators, and high-frequency ventilation (HFV) have not clearly been shown to improve clinical outcomes with routine use in ALI/ARDS, many have suggested they be reserved as "rescue therapies" for patients with severe ALI/ARDS (3, 4) .
Whereas the term rescue therapies suggests that these strategies are reserved until patients have not had success with more conventional measures, little is known about how physicians actually use these strategies in practice, or whether their use as a rescue therapy for patients with ARDS improves outcomes.
The present study addresses these questions by investigating utilization patterns and outcomes associated with use of rescue therapies in subjects enrolled in six National Heart, Lung, and Blood Institute ARDS Clinical Trials Network (ARDSNet) studies.
States; details regarding protocols of ARDSNet studies can be found at the ARDSNet web site. All study procedures were approved by the Boston University School of Medicine Institutional Review Board as well as the National Heart, Lung, and Blood Institute Biological Specimen and Data Repository Information Coordinating Center.
Study Design
Protocols for the ARDSNet trials stipulated that use of prespecified "experimental therapies" be recorded daily for all subjects. Use of these therapies was not restricted by trial protocols. "Experimental therapies" included prone positioning, inhaled nitric oxide (iNO), inhaled prostacyclin, extracorporeal membrane oxygenation, HFV, partial liquid ventilation, surfactant, and intravenous oxygen. Because these therapies were used per the discretion of the treating medical team after randomization to a trial intervention, we considered the "experimental therapy" as "rescue therapy" for the purposes of this study. Partial liquid ventilation, surfactant, or intravenous oxygen were provided to one or fewer subjects and were excluded from this analysis.
Our study had three objectives. First, we determined patient characteristics and practice patterns associated with use of rescue therapy in the cohort of ARDSNet trial subjects. Second, we performed a matched cohort study comparing survival of subjects who received rescue therapy to propensity scorematched controls who did not receive rescue therapy. Third, we compared survival between subjects who received prone positioning vs. those who received inhaled vasodilator (iNO and inhaled prostacyclin) (11) therapy. Inhalational vasodilator therapies were combined because of the small number of subjects (n ϭ 5) receiving inhaled prostacyclin. Subjects receiving more than one rescue therapy were categorized by the first therapy initiated.
Subject Characteristics and Practice Patterns
Prerandomization (baseline) subject characteristics of those who received rescue therapy were compared to those not receiving rescue. These characteristics included demographics, comorbidities, lung injury risk factors, mechanical ventilation characteristics, study randomization groups, and duration of intensive care unit stay before study enrollment. Simplified Acute Physiology II Scores (12) and Brussels organ dysfunction scores (13) 
Survival After Rescue Therapy Versus No Rescue Therapy
Propensity scores for the probability of receiving rescue therapy were calculated for all subjects. Rescue therapy subjects were matched to two "controls" with the closest propensity score who did not receive rescue therapy. To avoid "immortal time bias" (14) , survival time from the initiation of rescue therapy-or a matched index date for controls-was compared between subjects with rescue therapy and propensity score-matched controls (15) . Additional confounders measured at the rescue/index date were added as covariates to the survival analysis of the matched cohort to control for confounding attributable to changes in condition from baseline to rescue/index date. Thus, the potential for confounding by indication from variables present both at baseline and at the rescue/index date were addressed in the final analyses. We performed subgroup analyses of survival for prone positioning in subjects with PaO 2 /FIO 2 Ͻ100 and assessed for interaction between PaO 2 /FIO 2 , rescue therapy status, and survival (16) .
Survival After Prone Positioning Versus Inhaled Vasodilator Therapy
We compared survival between the two most commonly utilized rescue therapies: prone positioning and inhaled vasodilators. Baseline characteristics were used to generate propensity scores for receipt of either therapy. Models were then constructed using the propensity score for rescue therapy type to control for confounding attributable to both baseline variables and covariates measured at the time of rescue.
Statistical Analyses
The primary outcome of this study was the comparison of survival after rescue/index date between those who received rescue therapy or their propensity score-matched controls. With an ␣ of 0.05 and two controls per subject with rescue therapy, 330 total subjects were needed to detect a hazard ratio (HR) for mortality of 0.67 for rescue compared with no rescue with 80% power.
Continuous data were non-Gaussian and were compared using nonparametric Wilcoxon rank-sum or Kruskal-Wallis tests, as appropriate. Categorical data were compared with Fisher's exact test. Tests for time trends were calculated using logistic regression with study order as a continuous variable while simultaneously controlling for the individual study as a categorical variable. Details regarding construction of propensity scores and Cox proportional hazards models can be found in the Supplemental Digital Content. SAS 9.1 (Cary, NC) was used for all statistical analyses, with the exception of survival plots, which were generated with PASW statistics 18.0 (Chicago, IL).
RESULTS

Subject Characteristics and Practice Patterns
Baseline data for the 2632 subjects included in the study cohort are shown in Table 1 ; 166 of 2632 (6.3%) subjects received rescue therapy. As shown in Table  1 , subjects who received rescue therapy were younger, had lower PaO 2 /FIO 2 , higher positive end-expiratory pressure, and higher peak and plateau airway pressures. In addition, those administered rescue therapy were more likely to be of nonwhite racial background and to have pneumonia as an ALI risk factor. Although the relationship was not linear, the proportion of subjects receiving inhaled vasodilators increased over time whereas use of prone positioning decreased (Table 2) . At the time of rescue therapy, 25% of subjects had PaO 2 /FIO 2 Ͻ55, whereas median PaO 2 /FIO 2 was 80. No differences were found in use of rescue therapy according to study randomization groups (Supplementary Table I ). No significant differences in survival were identified comparing rescue to nonrescue subjects matched on propensity scores (HR for mortality after rescue therapy: 1.36; 95% CI, 0.90 -2.05; p ϭ .14; n ϭ 311; Figure 1A ). After further adjustment for confounding variables present at the rescue/index date (nonpulmonary Brussels score, PaO 2 /FIO 2 , positive end-expiratory pressure, peak airway pressure), the effect estimate for mortality associated with rescue therapy was further attenuated (HR, 1.10; 95% CI, 0.67-1.78; n ϭ 218; p ϭ .72; Figure 1B) . In subgroup analysis of survival among subjects with PaO 2 /FIO 2 Ͻ100, prone position HR was 0.97 (95% CI, 0.53-1.79; p ϭ .94) compared with no rescue. Overall, there was no evidence for interaction between PaO 2 /FIO 2 , rescue therapy, and survival (p ϭ .72).
Rescue Therapy Compared With No Rescue Therapy
Comparisons Among Rescue Therapies
Of the 166 subjects receiving rescue therapy, 97 (58%) received prone positioning, 47 (28%) received inhaled vasodilator therapy, 12 (7.2%) received HFV, and 10 (6.0%) received extracorporeal membrane oxygenation. Twenty-five (15%) subjects received two rescue therapies. Table 3 demonstrates values for variables at baseline and rescue date stratified by type of rescue therapy.
Comparisons Between Prone and Inhaled Vasodilator Therapy
Subjects who received inhaled vasodilators were younger than those treated with prone position (prone 48.3 Ϯ 15.0 vs. inhaled vasodilator 40.6 Ϯ 15.5 yrs; p ϭ .0085) and had higher peak airway pressures at time of rescue (prone 37.0 Ϯ 9.0 vs. inhaled vasodilator 43.8 Ϯ 13.8 cm H 2 O; p ϭ .005). Significant multivariate predictors of prone positioning as compared with inhaled vasodilator therapy included presence of sepsis (OR, 0.14; 95% CI, 0.03-0.73; p ϭ .02), peak airway pressure (OR per 5-cm H 2 O increase 0.62; 95% CI, 0.46 -0.84; p ϭ .002), and study order (OR per subsequent ARDSNet study: 0.32; 95% CI, 0.14 -0.70; p ϭ .004). The final propensity score model for prone positioning as compared with inhaled vasodilator (Hosmer-Lemeshow chi-square ϭ 1.54; c statistic ϭ 0.85) also included the following variables with p Ͻ .20: age (OR per 10 yrs: 1.50; 95% CI, 0.95-2.36; p ϭ .079) and presence of Figure 2A ). After adjustment for the propensity score for use of prone position vs. inhaled vasodilator, prone position was associated with HR of 0.87 (95% CI, 0.86 -2.10; p ϭ .76; n ϭ 86; Figure 2B) ; adjusting further for peak airway pressure and PaO 2 /FIO 2 at time of rescue, prone positioning was associated with HR of 0.95 (95% CI, 0.35-2.57; n ϭ 65; p ϭ .92) for survival as compared with inhaled vasodilator therapy.
DISCUSSION
This study demonstrates that adjunctive rescue therapies were used in a minority of patients (6.3%) in the ARDSNet trials. Younger patients with more severe abnormalities in oxygenation and elevated airway pressures were more likely to receive rescue therapy. Prone positioning was most common but was less likely to be used compared with inhaled vasodilators in those with sepsis or higher airway pressures. Although changes over time were not linear, utilization of inhaled vasodilators increased and prone positioning decreased. Within the limits of observational analyses, no differences in adjusted outcomes were seen between those who received rescue therapy or those who did not, or between rescue modalities.
Few studies have investigated ARDS rescue therapy practice patterns. The International Study of Mechanical Ventilation, a cross-sectional study of mechanical ventilation practices, reported that use of prone positioning declined from 13% of ARDS patients in 1998 to 7% in 2004 (17) . Our data also show a reduction in prone therapy over time. Observational studies of ARDS resulting from the 2009 H1N1 influenza pandemic reported widely variable utilization of prone positioning, from 3% of mechanically ventilated patients in the Canadian outbreak (18) to 33% in Spain (19) . In a survey of Canadian Critical Care Trial Group physicians, the proportion of respondents who stated they always or sometimes used inhaled vasodilator therapy (43%) or prone positioning (61.8%) in ARDS (20) appears substantially greater than that observed the ARDSNet centers. Additionally, rescue therapy utilization reported in international, multicenter, randomized, controlled trials of ALI therapies also support higher rates of rescue therapy than observed in ARDSNet. For example, in trials comparing high vs. lower positive end-expiratory pressure strategies, rescue therapies (mostly iNO) were utilized in 26.6% of the French EXPRESS trial subjects (21) and in 10% of LOVS trial subjects (22) . In comparison, only 5.8% of subjects enrolled in the ARDSNet Assessment of Low Tidal Volume and End-Expiratory Volume to Obviate Lung Injury trial received rescue (mostly prone posi- tion). These comparisons suggest a lower rate of use of rescue therapy in the United States as compared with previously reported European-based and Canadian-based studies. Overall, prone positioning, which requires no specific equipment, was most common. In multivariate analysis, subjects were more likely to receive inhaled vasodilators than prone positioning if they had higher peak airway pressures or sepsis. Reasons for an association between inhaled vasodilators and sepsis are not clear. It is possible that practitioners were more hesitant to use prone positioning during sepsis because of fear of central line disruption or abdominal sources of sepsis that would make prone positioning more difficult. Additionally, contemporaneous evidence suggested that inhaled nitric oxide responders may have lower mortality in sepsis-related ARDS (23) . However, the theoretical benefits of prone positioning may be more apparent in patients without direct lung injury who may have more "recruitable" lung (24) . Subjects with higher peak airway pressures were less likely to be prone, perhaps because of the possibility that prone positioning may further elevate peak pressures through loss of chest wall compliance (25) .
What conclusions might be drawn from these observations of rescue therapy practice patterns? First is that use of rescue therapy appears quite variable; comparison with other clinical trials and observational studies suggests large variations in rescue therapy utilization. Second is that use of these therapies does not appear to be associated with clinical trial evidence for mortality outcomes; despite multiple randomized controlled trials that did not demonstrate mortality benefits to iNO (26) , prone positioning (27, 28) , and HFV (29) in ARDS contemporaneous to these studies, overall use of rescue therapies did not change. Third, utilization in those subjects with poor oxygenation and high airway pressures was in line with evidence that rescue therapies do improve oxygenation (25, 29, 30) . At the time of rescue therapy, however, only 25% of subjects had PaO 2 / FIO 2 Ͻ55, whereas median PaO 2 /FIO 2 was 80. Therefore, the majority of those receiving rescue therapies appeared to have severe but not necessarily refractory oxygenation deficits less than the ARDSNet trial protocol goal PaO 2 Ͼ55 mm Hg. Similar to randomized controlled trials investigating prone positioning and iNO as a primary strategy in ALI/ARDS, we did not find a survival benefit to these interventions when used as rescue therapies. In addition, we did not find evidence for superiority of one rescue therapy over another (e.g., prone positioning vs. inhaled vasodilator therapy; we did not have sufficient HFV or extracorporeal membrane oxygenation patients for meaningful outcomes comparisons). Recent meta-analyses have shown increased renal failure and no survival benefit with iNO in patients with ARDS (30) . However, there is emerging evidence for lower mortality with prone positioning in the subgroup of subjects with PaO 2 /FIO 2 Ͻ100 (16). In addition, a recent metaanalysis has suggested a mortality benefit for HFV vs. conventional ventilation, although tidal volumes of 6 mL/kg were not utilized in the control groups of these trials (31). We could not confirm these findings or show an interaction between outcomes of rescue therapy and PaO 2 -to-FIO 2 ratio. This may be attributable to differences between early and protocolized use of the therapies in directed randomized controlled trials as compared with variable timing and duration when used ad libitum in this study.
Our study has limitations. First, it is unclear if clinical practice during ARDSNet randomized controlled trials mirrors that of routine practice, even if therapy is not limited by protocol. The lower rates of rescue therapy seen in this study compared with previous studies may reflect lower utilization of rescue in a clinical trial setting. Additionally, attempts made to control for confounding may be limited by unmeasured confounding by indication for rescue therapy. Data provided by BIOLINCC does not identify a subject's study site; this information would have added important information regarding practice pattern variation. Finally, the sample size and power of analyses controlled for multiple potentially confounding variables was limited by missing data.
Patients with poor oxygenation or elevated airway pressures despite evidencebased lung-protective ventilator strategies present considerable management difficulties. Rescue therapies were utilized relatively infrequently in the ARDSNet trials and were targeted to younger patients with poor oxygenation or elevated airway pressures or both. During the timeframe of this study, there was a trend toward decreased utilization of prone positioning and increased use of inhaled vasodilators, a trend that may not be supported by recent meta-analyses of these interventions. We did not find evidence of a survival benefit with nonprotocolized use of rescue therapy in ALI and ARDS. Further studies must be performed to assess the benefits and harms of rescue therapies in patients with ARDS who have not responded to conventional measures. 
